Cargando…

Modulation of TRAIL resistance in colon carcinoma cells: Different contributions of DR4 and DR5

BACKGROUND: rhTRAIL is a therapeutic agent, derived from the TRAIL cytokine, which induces apoptosis in cancer cells by activating the membrane death receptors 4 and 5 (DR4 and DR5). Here, we investigated each receptor's contribution to rhTRAIL sensitivity and rhTRAIL resistance. We assessed wh...

Descripción completa

Detalles Bibliográficos
Autores principales: van Geelen, Caroline MM, Pennarun, Bodvael, Le, Phuong TK, de Vries, Elisabeth GE, de Jong, Steven
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3045356/
https://www.ncbi.nlm.nih.gov/pubmed/21272366
http://dx.doi.org/10.1186/1471-2407-11-39
_version_ 1782198819115499520
author van Geelen, Caroline MM
Pennarun, Bodvael
Le, Phuong TK
de Vries, Elisabeth GE
de Jong, Steven
author_facet van Geelen, Caroline MM
Pennarun, Bodvael
Le, Phuong TK
de Vries, Elisabeth GE
de Jong, Steven
author_sort van Geelen, Caroline MM
collection PubMed
description BACKGROUND: rhTRAIL is a therapeutic agent, derived from the TRAIL cytokine, which induces apoptosis in cancer cells by activating the membrane death receptors 4 and 5 (DR4 and DR5). Here, we investigated each receptor's contribution to rhTRAIL sensitivity and rhTRAIL resistance. We assessed whether agonistic DR4 or DR5 antibodies could be used to circumvent rhTRAIL resistance, alone or in combination with various chemotherapies. METHODS: Our study was performed in an isogenic model comprised of the SW948 human colon carcinoma cell line and its rhTRAIL resistant sub-line SW948-TR. Effects of rhTRAIL and agonistic DR4/DR5 antibodies on cell viability were measured using MTT assays and identification of morphological changes characteristic of apoptosis, after acridine orange staining. Sensitivity to the different death receptor ligands was stimulated using pretreatment with the cytokine IFN-gamma and the proteasome inhibitor MG-132. To investigate the mechanisms underlying the changes in rhTRAIL sensitivity, alterations in expression levels of targets of interest were measured by Western blot analysis. Co-immunoprecipitation was used to determine the composition of the death-inducing signalling complex at the cell membrane. RESULTS: SW948 cells were sensitive to all three of the DR-targeting agents tested, although the agonistic DR5 antibody induced only weak caspase 8 cleavage and limited apoptosis. Surprisingly, agonistic DR4 and DR5 antibodies induced equivalent DISC formation and caspase 8 cleavage at the level of their individual receptors, suggesting impairment of further caspase 8 processing upon DR5 stimulation. SW948-TR cells were cross-resistant to all DR-targeting agents as a result of decreased caspase 8 expression levels. Caspase 8 protein expression was restored by MG-132 and IFN-gamma pretreatment, which also re-established sensitivity to rhTRAIL and agonistic DR4 antibody in SW948-TR. Surprisingly, MG-132 but not IFN-gamma could also increase DR5-mediated apoptosis in SW948-TR. CONCLUSIONS: These results highlight a critical difference between DR4- and DR5-mediated apoptotic signaling modulation, with possible implications for future combinatorial regimens.
format Text
id pubmed-3045356
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30453562011-02-26 Modulation of TRAIL resistance in colon carcinoma cells: Different contributions of DR4 and DR5 van Geelen, Caroline MM Pennarun, Bodvael Le, Phuong TK de Vries, Elisabeth GE de Jong, Steven BMC Cancer Research Article BACKGROUND: rhTRAIL is a therapeutic agent, derived from the TRAIL cytokine, which induces apoptosis in cancer cells by activating the membrane death receptors 4 and 5 (DR4 and DR5). Here, we investigated each receptor's contribution to rhTRAIL sensitivity and rhTRAIL resistance. We assessed whether agonistic DR4 or DR5 antibodies could be used to circumvent rhTRAIL resistance, alone or in combination with various chemotherapies. METHODS: Our study was performed in an isogenic model comprised of the SW948 human colon carcinoma cell line and its rhTRAIL resistant sub-line SW948-TR. Effects of rhTRAIL and agonistic DR4/DR5 antibodies on cell viability were measured using MTT assays and identification of morphological changes characteristic of apoptosis, after acridine orange staining. Sensitivity to the different death receptor ligands was stimulated using pretreatment with the cytokine IFN-gamma and the proteasome inhibitor MG-132. To investigate the mechanisms underlying the changes in rhTRAIL sensitivity, alterations in expression levels of targets of interest were measured by Western blot analysis. Co-immunoprecipitation was used to determine the composition of the death-inducing signalling complex at the cell membrane. RESULTS: SW948 cells were sensitive to all three of the DR-targeting agents tested, although the agonistic DR5 antibody induced only weak caspase 8 cleavage and limited apoptosis. Surprisingly, agonistic DR4 and DR5 antibodies induced equivalent DISC formation and caspase 8 cleavage at the level of their individual receptors, suggesting impairment of further caspase 8 processing upon DR5 stimulation. SW948-TR cells were cross-resistant to all DR-targeting agents as a result of decreased caspase 8 expression levels. Caspase 8 protein expression was restored by MG-132 and IFN-gamma pretreatment, which also re-established sensitivity to rhTRAIL and agonistic DR4 antibody in SW948-TR. Surprisingly, MG-132 but not IFN-gamma could also increase DR5-mediated apoptosis in SW948-TR. CONCLUSIONS: These results highlight a critical difference between DR4- and DR5-mediated apoptotic signaling modulation, with possible implications for future combinatorial regimens. BioMed Central 2011-01-27 /pmc/articles/PMC3045356/ /pubmed/21272366 http://dx.doi.org/10.1186/1471-2407-11-39 Text en Copyright ©2011 van Geelen et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
van Geelen, Caroline MM
Pennarun, Bodvael
Le, Phuong TK
de Vries, Elisabeth GE
de Jong, Steven
Modulation of TRAIL resistance in colon carcinoma cells: Different contributions of DR4 and DR5
title Modulation of TRAIL resistance in colon carcinoma cells: Different contributions of DR4 and DR5
title_full Modulation of TRAIL resistance in colon carcinoma cells: Different contributions of DR4 and DR5
title_fullStr Modulation of TRAIL resistance in colon carcinoma cells: Different contributions of DR4 and DR5
title_full_unstemmed Modulation of TRAIL resistance in colon carcinoma cells: Different contributions of DR4 and DR5
title_short Modulation of TRAIL resistance in colon carcinoma cells: Different contributions of DR4 and DR5
title_sort modulation of trail resistance in colon carcinoma cells: different contributions of dr4 and dr5
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3045356/
https://www.ncbi.nlm.nih.gov/pubmed/21272366
http://dx.doi.org/10.1186/1471-2407-11-39
work_keys_str_mv AT vangeelencarolinemm modulationoftrailresistanceincoloncarcinomacellsdifferentcontributionsofdr4anddr5
AT pennarunbodvael modulationoftrailresistanceincoloncarcinomacellsdifferentcontributionsofdr4anddr5
AT lephuongtk modulationoftrailresistanceincoloncarcinomacellsdifferentcontributionsofdr4anddr5
AT devrieselisabethge modulationoftrailresistanceincoloncarcinomacellsdifferentcontributionsofdr4anddr5
AT dejongsteven modulationoftrailresistanceincoloncarcinomacellsdifferentcontributionsofdr4anddr5